Moebius Medical is a clinical stage biotechnology company that has used patented technology licensed from the Hebrew University, Technion and Hadassah Medical Center to develop novel pain relief treatments for osteoarthritis patients.

Moebius’s lead product, MM-II, is a patent-protected intra-articular biolubricant injection that is proving effective in the treatment of mild-to-moderate symptomatic knee osteoarthritis (OA). 
 
In 2016, Moebius Medical entered into an exclusive worldwide licensing deal for MM-II with India's Sun Pharmaceutical Industries Ltd. to develop MM-II.